Journal of Gastrointestinal Surgery

, Volume 17, Issue 9, pp 1553–1556 | Cite as

Gastroparesis: What is the Current State-of-the-Art for Evaluation and Medical Management? What are the Results?

2012 SSAT Other

Abstract

Gastroparesis is a chronic motility disorder that leads to delayed gastric emptying and negatively impacts morbidity, mortality, and quality of life. This paper provides an overview of the pathophysiology leading to symptoms in gastroparesis, discusses tests for diagnosis, and examines the evidence behind different treatment options for gastroparesis. Although delayed gastric emptying is the cardinal finding in gastroparesis, other physiologic abnormalities may contribute to the pathogenesis of symptoms. Gastric emptying scintigraphy is considered the gold standard for the diagnosis of gastroparesis but novel tests are currently available. Although metoclopramide is the only FDA approved medication to treat gastroparesis, alternative therapeutic options are available and should be tailored according to symptoms as well as physiologic abnormalities.

Keywords

Gastroparesis Idiopathic gastroparesis Diabetic gastroparesis Post-surgical gastroparesis 

References

  1. 1.
    Jung HK, Choung RS, Locke GR, 3rd, Schleck CD, Zinsmeister AR, Szarka LA, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009 Apr;136(4):1225–33.Google Scholar
  2. 2.
    Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004 Nov;127(5):1592–622.Google Scholar
  3. 3.
    Takahashi T, Nakamura K, Itoh H, Sima AA, Owyang C. Impaired expression of nitric oxide synthase in the gastric myenteric plexus of spontaneously diabetic rats. Gastroenterology. 1997 Nov;113(5):1535–44.Google Scholar
  4. 4.
    Grover M, Farrugia G, Lurken MS, Bernard CE, Faussone-Pellegrini MS, Smyrk TC, et al. Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology. May;140(5):1575–85. e8.Google Scholar
  5. 5.
    Kumar A, Attaluri A, Hashmi S, Schulze KS, Rao SS. Visceral hypersensitivity and impaired accommodation in refractory diabetic gastroparesis. Neurogastroenterol Motil. 2008 Jun;20(6):635–42.Google Scholar
  6. 6.
    Chen J, McCallum RW. Gastric slow wave abnormalities in patients with gastroparesis. The American journal of gastroenterology. 1992 Apr;87(4):477–82.Google Scholar
  7. 7.
    Abell TL, Camilleri M, Donohoe K, Hasler WL, Lin HC, Maurer AH, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. The American journal of gastroenterology. 2008 Mar;103(3):753–63.Google Scholar
  8. 8.
    Kuo B, McCallum RW, Koch KL, Sitrin MD, Wo JM, Chey WD, et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Alimentary pharmacology & therapeutics. 2008 Jan 15;27(2):186–96.Google Scholar
  9. 9.
    Perkel MS, Moore C, Hersh T, Davidson ED. Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study. Digestive diseases and sciences. 1979 Sep;24(9):662–6.Google Scholar
  10. 10.
    Snape WJ, Jr., Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Annals of internal medicine. 1982 Apr;96(4):444–6.Google Scholar
  11. 11.
    Lata PF, Pigarelli DL. Chronic metoclopramide therapy for diabetic gastroparesis. The Annals of pharmacotherapy. 2003 Jan;37(1):122–6.Google Scholar
  12. 12.
    Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. Expert review of endocrinology & metabolism. 5(5):653–62.Google Scholar
  13. 13.
    Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. The American journal of gastroenterology. 1999 May;94(5):1230–4.Google Scholar
  14. 14.
    Sugumar A, Singh A, Pasricha PJ. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol. 2008 Jul;6(7):726–33.Google Scholar
  15. 15.
    Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. The American journal of gastroenterology. 2003 Feb;98(2):259–63.Google Scholar
  16. 16.
    Mathis C, Malbert CH. Gastric but not duodenal motor effects of oral erythromycin are dose related. Neurogastroenterol Motil. 1995 Mar;7(1):47–54.Google Scholar
  17. 17.
    Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. The American journal of gastroenterology. 2008 Feb;103(2):416–23.Google Scholar
  18. 18.
    Coleski R, Anderson MA, Hasler WL. Factors associated with symptom response to pyloric injection of botulinum toxin in a large series of gastroparesis patients. Digestive diseases and sciences. 2009 Dec;54(12):2634–42.Google Scholar
  19. 19.
    Sawhney MS, Prakash C, Lustman PJ, Clouse RE. Tricyclic antidepressants for chronic vomiting in diabetic patients. Digestive diseases and sciences. 2007 Feb;52(2):418–24.Google Scholar
  20. 20.
    Ejskjaer N, Dimcevski G, Wo J, Hellstrom PM, Gormsen LC, Sarosiek I, et al. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol Motil. Oct;22(10):1069-e281.Google Scholar
  21. 21.
    Matsueda K, Hongo M, Tack J, Saito Y, Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. Jun;61(6):821–8.Google Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2013

Authors and Affiliations

  1. 1.University of VermontBurlingtonUSA

Personalised recommendations